Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.41 - $8.69 $649,333 - $880,297
101,300 New
101,300 $769,000
Q1 2024

May 15, 2024

SELL
$4.89 - $7.65 $1.91 Million - $2.99 Million
-390,600 Reduced 66.0%
201,200 $1.02 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $2.44 Million - $3.32 Million
490,900 Added 486.52%
591,800 $3.54 Million
Q2 2023

Aug 14, 2023

SELL
$6.96 - $8.81 $963,264 - $1.22 Million
-138,400 Reduced 57.84%
100,900 $710,000
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $1.1 Million - $1.64 Million
138,600 Added 137.64%
239,300 $2 Million
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $1.06 Million - $1.43 Million
100,700 New
100,700 $1.16 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.